Several reports indicate that chemo-resistant cancer cells become highly adapted to intrinsic oxidative stress by up-regulating their antioxidant systems, which causes an increase of intracellular GSH content. Doxorubicin is one of the most widely used drugs for tumor treatment, able to kill cancer cells through several mechanisms. However, doxorubicin use is limited by its toxicity and cancer resistance. Therefore, new therapeutic strategies able to reduce doses and to overcome chemo-resistance are needed. A new class of glutathione-responsive cyclodextrin nanosponges (GSH-NS), is able to release anticancer drugs preferentially in cells having high GSH content. Doxorubicin-loaded GSH-NS, in the cancer cells with high GSH content, inhibited clonogenic growth, cell viability, topoisomerase II activity and induced DNA damage with higher effectiveness than free drug. Moreover, GSH-NS reduced the development of human tumor in xenograft models more than free drug. These characteristics indicate that GSH-NS can be a suitable drug delivery carrier for future applications in cancer therapy.
Drug Delivery Systems , Drug Resistance, Neoplasm/genetics , Neoplasms/drug therapy , Oxidative Stress/drug effects , Animals , Antioxidants/chemistry , Antioxidants/metabolism , Cell Line, Tumor , Cell Survival , DNA Damage/drug effects , Doxorubicin/administration & dosage , Doxorubicin/chemistry , Glutathione/chemistry , Glutathione/metabolism , Humans , Mice , Nanostructures/administration & dosage , Nanostructures/chemistry , Neoplasms/metabolism , Neoplasms/pathology , Xenograft Model Antitumor Assays
